FLUENT Clears Major Hurdle in Vireo Tie-Up Amid Steep Debt Costs

TAMPA, Fla. – November 04, 2026 – In a move that underscores both the aggressive consolidation sweeping the cannabis sector and the punishing cost of capital required to fuel it, FLUENT Corp. has secured a critical amendment to its senior secured credit agreement. The amendment, negotiated with administrative agent Chicago Atlantic Financial Services, LLC, provides the necessary lender consent for FLUENT’s pending acquisition by Vireo Growth Inc., while injecting an immediate US$10.5 million in term loans into the vertically integrated multi-state operator.

The execution of this credit amendment satisfies a mandatory closing condition for the all-stock arrangement, bringing the two cannabis operators one step closer to finalizing a merger that will significantly alter the competitive landscape, particularly in the lucrative Florida medical market. However, the terms of the new capital highlight the steep financial toll that federal banking prohibitions continue to exact on the industry.

Paving the Way for a Cannabis Giant

The planned arrangement between FLUENT and Vireo Growth Inc. represents a strategic marriage designed to achieve massive scale in a fragmented industry. Under the terms of the all-stock transaction, Vireo will acquire all issued and outstanding common shares of FLUENT, with FLUENT shareholders receiving 0.0705359 of a Vireo subordinate voting share for every FLUENT share held.

For Vireo, the acquisition is a calculated play to dominate limited-license markets. The combined entity is projected to operate approximately 74 retail stores and boast 144,000 square feet of cultivation and production canopy. The crown jewel of this combination is Florida, where FLUENT has steadily built a robust footprint under its Medical Marijuana Treatment Center license. By absorbing FLUENT’s 34 active retail locations and six cultivation and manufacturing facilities, Vireo dramatically accelerates its penetration into the Sunshine State.

"Scale is no longer just a competitive advantage in markets like Florida; it is an absolute necessity for survival," noted one cannabis industry analyst familiar with the transaction. "Vireo has been on an aggressive acquisition tear, and bringing FLUENT into its ecosystem allows it to instantly command a massive share of patient volume without having to build out new infrastructure from scratch."

The merger, which received an overwhelming 82.49% approval from FLUENT shareholders in July, is expected to close in the fourth quarter of 2026. Upon completion, FLUENT’s common shares will be delisted from the Canadian Securities Exchange and the OTCQB Venture Market, ending its tenure as a standalone public reporting issuer.

The Steep Price of Consolidation

While the strategic merits of the merger are clear, the financial mechanics required to get it across the finish line reveal the harsh realities of cannabis financing. To secure the $10.5 million lifeline and lender consent, FLUENT had to accept borrowing terms that would be considered exorbitant in almost any other traditional sector.

The additional term loans carry a blended annual interest rate of 13%, structured as a 12.00% cash interest rate and a 1.00% payment-in-kind (PIK) rate. Furthermore, the capital is subject to a 2.00% original issue discount payable at closing and a 2.00% exit fee due upon maturity, prepayment, or acceleration.

These double-digit rates and heavy fee structures are emblematic of the leverage held by non-bank lenders and private credit funds in the cannabis space. Because major financial institutions remain sidelined by the federal classification of cannabis as a controlled substance, alternative asset managers like Chicago Atlantic have stepped in to fill the void—at a premium.

"When you are locked out of traditional commercial banking, your cost of capital is dictated by specialized private credit funds that price in the perceived regulatory risk," explained a private equity executive focused on distressed cannabis assets. "A 13% blended rate, plus four points in total fees, is actually right down the fairway for a mid-sized operator navigating a complex merger in today's environment. The lenders know these companies have few alternatives."

Restructuring and Regulatory Maneuvers

The credit amendment is just one piece of a broader, highly complex restructuring puzzle FLUENT has had to solve to make the Vireo arrangement viable.

To alleviate its debt burden and align its capital structure with Vireo’s requirements, FLUENT previously entered into a credit equitization agreement with its senior secured lenders. This maneuver will convert US$30 million of outstanding indebtedness into FLUENT shares, which will subsequently convert into Vireo shares upon the transaction's closing. This debt-for-equity swap is a critical de-leveraging event that makes the absorption of FLUENT much more palatable for Vireo’s balance sheet.

Simultaneously, FLUENT has had to navigate the thorny issue of overlapping state licenses. In New York, where Vireo already maintains a significant presence encompassing cultivation, manufacturing, and retail infrastructure, FLUENT was forced to divest. The company entered into a definitive agreement to sell its New York cannabis license and operating assets, formerly operating as Etain, LLC, to an unnamed third-party operator. This strategic offloading is designed specifically to satisfy the New York State Cannabis Control Board's strict regulations regarding ownership concentration and to clear the regulatory runway for the Vireo merger.

Navigating the Industry's 'Debt Wall'

FLUENT’s reliance on high-cost private credit to bridge the gap to its acquisition is a microcosm of a much larger crisis looming over the U.S. cannabis industry. Market watchers estimate that the sector is currently staring down a debt wall of approximately $6 billion in loans maturing by the end of 2026.

Many of these loans were underwritten during the pandemic-era cannabis boom, when valuations were sky-high and capital flowed more freely. Today, with equity valuations depressed and operational cash flows squeezed by tax burdens and price compression, refinancing this debt has become a monumental challenge. Companies unable to secure buyouts are increasingly forced into amend-and-extend agreements, renegotiating their debt at even higher interest rates simply to stave off default.

While the recent move by the Drug Enforcement Administration to recognize federal DEA registrations for Vireo's medical dispensaries under the anticipated Schedule III framework signals long-term regulatory relief, the immediate financial environment remains brutal. Until federal rescheduling is finalized and banking restrictions are formally lifted, operators will continue to rely on specialized alternative lenders to fund operations and execute mergers.

For FLUENT, the steep cost of its latest credit amendment is the price of admission for a safe harbor. By securing the necessary capital and lender consent, the company has effectively guaranteed its integration into a larger, better-capitalized operator, ensuring its assets and brands will continue to compete in an increasingly consolidated market.